This page shows the latest mongersen news and features for those working in and with pharma, biotech and healthcare.
The company’s psoriasis drug Otezla is also underperforming, and another blockbuster candidate mongersen failed in phase III.
other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
No results were found
We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...